UBS analyst David Lai initiated coverage of Immunocore (IMCR) with a Sell rating and $24 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. The analyst says moderate Kimmtrak growth and looming competition will likely to put shares of Immunocore under pressure.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore price target lowered to $74 from $80 at Morgan Stanley
- Immunocore downgraded to Neutral from Buy at Guggenheim
- Immunocore downgraded at Guggenheim with trajectory for Kimmtrak appreciated
- Immunocore presents Phase 1 data of brenetafusp in ovarian cancer
- Immunocore CFO Brian Di Donato to depart